The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances

How to cite

Finkelstein, Amy; Yokum, David; Sacarny, Adam. 2014. "The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances." AEA RCT Registry. AEARCTR-0000525. https://doi.org/10.1257/rct.525-7.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Amy Finkelstein* , David Yokum , Adam Sacarny

* Primary investigator

Registry ID
AEARCTR-0000525
DOI
https://doi.org/10.1257/rct.525-7.0
First registered
Last updated
Status
Completed
Trial dates
2014-08-01 – 2016-10-01
Countries
United States of America ()
Registry record
http://www.socialscienceregistry.org/trials/525

Abstract

Fraud and waste is estimated to cost the American health care system nearly $200 billion each year, and the public Medicare and Medicaid programs about $60 billion each year. This study will evaluate a new method for fighting fraud: mailing informative letters to outlier providers to notify them of their aberrant behavior. These letters are targeted at high prescribers of schedule II controlled substances in Medicare Part D. We will look at the effects of these letters on the behavior of providers and their patients. These effects are of substantial policy interest as they suggest how to best design anti-fraud policies. They are also of academic interest, shedding light on the behavior of physicians and their patients.

Intervention

A letter to outlier prescribers of schedule II controlled substances explaining that their prescribing behavior is highly unlike their peers.

Experimental design

An analysis was conducted to identify outlier prescribers of Schedule II controlled substances in the Medicare Part D. This analysis identified a group of prescribers, and they were then randomly allocated to a treatment or a control group.

Design details

Randomization method
Randomization done by computer (in Stata)
Randomization unit
The prescriber (e.g. physician, nurse, physician assistant, etc.)
Clusters
Approximately 1500 prescribers
Observations
Approximately 1500 prescribers
Arms
Approximately 750 providers in the control arm and 750 providers in the treatment arm
Primary outcomes
The primary outcome of the study is the effect of the letters on the prescribing of schedule II controlled substances over the 3 months following the initial sending of the letters. Prescribing is defined as the total “days supply” of schedule II controlled substances attributed to the prescriber, expressed in “30-day equivalents” i.e. divided by 30. We consider additional outcomes as well. Through these additional analyses, we hope to understand the totality of the effects of the letters. The secondary analysis for prescribers includes explorations of effect heterogeneity, quantile treatment effects, substitution toward other substances, and peer effects. We also conduct analyses looking at a cohort of patients who were treated by the prescribers prior to the sending of the letters. We will assign these patients to treatment and control groups based on whether their attributed prescriber was a treatment or control prescriber and study the total receipt of controlled substances by patients, heterogeneity in treatment effects, substitution toward other substances, and health outcomes.

Papers from this trial

  1. Sacarny, Adam, David Yokum, Amy Finkelstein, and Shantanu Agrawal. "Medicare Letters To Curb Overprescribing Of Controlled Substances Had No Detectable Effect On Providers." Health Affairs. 2016; 35(3); 471-479. doi:10.1377/hlthaff.2015.1025 http://content.healthaffairs.org/content/35/3/471

Cited by

No citation data available for this registration yet.

Keywords